SCIEX Supports Vital Cancer Prevention Research through Partnership with World Cancer Research Fund

SCIEX’s donation to the WCRF following several significant research partnerships with world-leading cancer scientists to advance the promise of Precision Medicine

FRAMINGHAM, MA — SCIEX a global leader in life science analytical technologies, has today announced its donation of US$11,000 to the World Cancer Research Fund (WCRF), which funds and supports vital scientific research into cancer prevention related to diet, weight and physical activity. This money was raised through SCIEX’s strong employee participation in the company’s annual engagement survey, where SCIEX committed to making a donation to this very important cause based on the number of survey responses collected. The WCRF cause is aligned with SCIEX’s vision of placing the power of life-changing answers into the hands of those who care, everywhere. The WCRF initiative is SCIEX’s latest contribution towards accelerating cancer research through providing the critical tools, expertise and partnerships that are urgently needed for developing more effective cancer therapies.

SCIEX’s generous donation will help the WCRF to fund expert scientific research to deepen our understanding of cancer risk and consequently how to reduce the incidence of the disease. As little as $13 allows the WCRF to reach 20 community healthcare workers with cancer prevention information, to improve patient care and outcomes.

“We’re incredibly grateful to SCIEX for their generous support in raising an impressive $11,000. It’s thanks to the amazing efforts of companies like SCIEX and their dedicated staff that we can continue to fund ground-breaking research into cancer prevention and survival, and help the public make more informed lifestyle choices to reduce their risk of cancer,” said Paul Fretwell, Head of Fundraising at World Cancer Research Fund.

To demonstrate its commitment to enabling scientists to discover and develop new ways to understand the biological root cause of diseases such as cancer, SCIEX has recently partnered with the University of Manchester to build the Stoller Biomarker Discovery Centre. As one of the biggest clinical proteomics facilities in the world, the Stoller Centre is spearheading a series of biomarker development projects and international collaborations. And last month, thanks to a new collaboration between SCIEX and the Children’s Medical Research Institute (CMRI), ProCan™, the Australian Cancer Research Foundation International Centre for the Proteome of Human Cancer opened its doors to enable discoveries around the causes of cancer, provide guidance for cancer treatment options and work to produce standard operating procedures for other facilities around the world. CMRI’s ProCan project is also included in the ‘Cancer Moonshot’ initiative, led by U.S. Vice President Joe Biden. Additionally, SCIEX is collaborating with the laboratory of Amanda Paulovich, M.D., PhD., at Fred Hutchinson Cancer Research Center, to develop targeted quantitative proteomic kits for cancer research.

(from left to right)Caroline Moye, Head of WCRF UK; Claire Sanderson, Team Leader, Sales, SCIEX; Russ Watts, Director, Business Development & Marketing EMEA, SCIEX; Kate Allen, Executive Director, Science and Public Affairs, WCRF International

“It is through SCIEX’s strong customer collaborations and partnerships that we can advance cancer research and ultimately aid in the promise of precision medicine,” said Jean-Paul Mangeolle, President of SCIEX. “We live this vision inside our workplace as well, by aligning our employee engagement programs, such as the SCIEX Run for Life, which also benefited WCRF, to support charities that work within Healthcare Research and Discovery. SCIEX is addressing some of the biggest issues in medicine to help improve peoples’ lives.”

View online Stoller Biomarker Discovery Centre Opening Symposium, which includes highlights from the opening and leading researcher scientific video presentations.